Boston Scientific reports heart-device problem
The medical device company said in a letter that 15 patients have received inappropriate electrical jolts from either Cognis or Teligen defibrillators, devices used to treat irregular heartbeats.
As many as 8,000 patients could be at risk, the company said. No deaths have been reported with the issue.
The shocks are mainly due to faulty leads, or wires connecting the devices to the heart, according to the March 23 letter. Not all wires used with the devices are made by Boston Scientific Corp.
Doctors can prevent the problem by turning off a sensor on the devices that can make them overly sensitive to unusual heart signals, states the letter, which was posted to a cardiology Web site.
The sensor records patient's breathing rhythms to give physicians extra information about their condition, though it is not necessary for medical treatment.
"Turning the respiratory sensor off eliminates the possibility of this inappropriate therapy occurring," said a company spokesman in a statement.
Implanted in the upper chest, defibrillators monitor the heart for deadly irregular heartbeats and use electrical jolts to shock it back to normal. They differ from pacemakers, which use lower-voltage electrical pulses to correct dangerously slow heart rhythms.
The approval of the Cognis and Teligen devices last year marked an important milestone for Boston Scientific as the first defibrillators launched under its own name.
The Natick, Mass.-based company entered the heart-regulating business in 2006 with the purchase of Guidant. But the acquisition was marred by controversy surrounding Guidant's Prizm defibrillators, which eventually sank sales for the entire sector. The Indianapolis-based Lilly fixed a flaw with its devices in 2002 but did not inform patients and physicians until three years later.
Citigroup analyst Matthew Dodds said the announcement could pressure product sales in the near term, "but the problem appears easily resolvable and it should not delay further sales."
Related News
KHNP is being considered for Bulgarian Nuclear Power Plant Project
SEOUL - Korea Hydro & Nuclear Power (KHNP) has been selected as one of the three strategic investor candidates for a Bulgarian nuclear power plant project.
The Bulgarian Energy Ministry selected KHNP of Korea, RosAtom of Russia and CNNC of China as strategic investor candidates for the construction of the Belene Nuclear Power Plant, KHNP said on Dec. 20. The Belene Nuclear Power Plant is the second nuclear power plant that Bulgaria plans to build following the 2,000-megawatt Kozloduy Nuclear Power Plant built in 1991 during the Soviet Union era. The project budget is estimated at 10 billion euros.
By being included…
